Location Directory

Clinical trials in Phoenix, Arizona

This page shows live ClinicalTrials.gov search results for Phoenix, Arizona, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

8144

Shown on this page

Current sort

Institutions in Phoenix

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Mayo Clinic

Live official records

Open in full search

Conditions: Prosthetic Joint Infection
Interventions: VT-X7 Treatment System with Tobramycin Sulfate, Standard of Care, Two-stage exchange arthroplasty, VT-X7 Treatment System with Vancomycin Hydrochloride; Combination Product · Drug · Procedure
Lead sponsor: Osteal Therapeutics, Inc.; Industry
Eligibility: 22 Years to 84 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 17
States / cities: Phoenix, Arizona • Torrance, California • Washington D.C., District of Columbia + 13 more

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions: Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab; Procedure · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 492
States / cities: Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 372 more

Conditions: Degenerative Disc Disease
Interventions: IDCT (rebonuputemcel), Sham (No Treatment); Biological · Other
Lead sponsor: DiscGenics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more

Conditions: Systemic Lupus Erythematosus
Interventions: Dapirolizumab pegol; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 16 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 34
States / cities: Birmingham, Alabama • Avondale, Arizona • Glendale, Arizona + 30 more

Conditions: Influenza
Interventions: MK-1406, Placebo; Combination Product
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 12 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 120
States / cities: Anniston, Alabama • Cullman, Alabama • Glendale, Arizona + 104 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 15
States / cities: Phoenix, Arizona • Burbank, California • Grand Junction, Colorado + 12 more

Conditions: Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Interventions: Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 303
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 226 more

Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Interventions: AR882 50 mg, AR882 75 mg, Placebo; Drug
Lead sponsor: Arthrosi Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 818 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 52
States / cities: Foley, Alabama • Anchorage, Alaska • Peoria, Arizona + 47 more

Conditions: Hidradenitis Suppurativa
Interventions: Brivekimig, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 17
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Northridge, California + 14 more

Conditions: Fabry Disease
Interventions: Not listed
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 9,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2034
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 70 more

Conditions: Diabetic Macular Edema
Interventions: Low dose BI 3812465, Medium dose BI 3812465, High dose BI 3812465; Biological
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 28
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Arcadia, California + 24 more

Conditions: Atrial Fibrillation
Interventions: AFSW Guided DOAC, Continuous DOAC therapy; Device · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 22 Years to 85 Years
Enrollment: 5,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 93
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 68 more

Clinical trials in Phoenix, Arizona

Filter and sort this location

Institutions in Phoenix

Live official records

Abbreviated Protocol for Two-Stage Exchange

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

Fabry Disease Registry & Pregnancy Sub-registry

A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation